U.S. markets closed

Vynleads, Inc. (VYND)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.00000.0000 (0.00%)
At close: 3:47PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0000
BidN/A x N/A
AskN/A x N/A
Day's Range1.0000 - 1.0000
52 Week Range0.4000 - 1.0000
Avg. Volume29
Market Cap11.6M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Vynleads Graduates to OTCQB Venture Market

      ROCK HILL, S.C., July 21, 2020 -- Vynleads, Inc. (the “Company” or “Vynleads”) (OTCQB: VYND), a health and wellness technology company dedicated to helping members thrive.

    • GlobeNewswire

      Vynleads’ DWD Protocol & Targeted Nutraceuticals Can Support Type-2 Diabetics Amidst Health Uncertainty

      Vynleads, Inc. (the “Company” or “Vynleads”) (VYND), a health and wellness technology company dedicated to helping members thrive naturally and stay out of the emergency room, reports that its “Done with Diabetes” (DWD) Protocol can help people with type-2 diabetes improve their overall health. The DWD Protocol is based on work at London’s Newcastle University by Dr. Roy Taylor, who showed that the remission of type-2 diabetes is linked to a loss of liver fat.